Clinical Trial Update: Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer [EARLY_Phase 1]

View source ↗

Summary

This EARLY Phase 1 clinical trial update describes a window trial of the fluorescent Panitumumab-IRDye800 agent for imaging in head and neck squamous cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Laryngeal Cancer
• Oral Cavity Cancer
• Pharyngeal Cancer

Drugs mentioned

• Panitumumab-IRDye800

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity | EARLY_Phase 1 | Status: RECRUITING